Eylea vs Lucentis
Side-by-side cost comparison based on Medicare Part D data
Eylea
Aflibercept
Manufactured by Regeneron
Lucentis
Ranibizumab
Manufactured by Genentech/Roche
Lucentis costs 13% less per claim than Eylea ($654.00 vs $752.00). A generic version of Lucentis is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Eylea | Lucentis |
|---|---|---|
| Avg Cost Per Claim | $752.00 | $654.00 |
| Total Medicare Spending | $3.7B | $1.1B |
| Total Beneficiaries | 685,000 | 245,000 |
| Total Claims | 4,860,000 | 1,680,000 |
| Annual Cost/Patient | $5,334.00 | $4,482.00 |
| Year-over-Year Change | -8.3% | -22.3% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Regeneron | Genentech/Roche |
| Condition | Eye Diseases | Eye Diseases |
| Generic Name | Aflibercept | Ranibizumab |
Eylea vs Lucentis: What the Data Shows
Eylea (Aflibercept) and Lucentis (Ranibizumab) are both used to treat eye diseases. Based on Medicare Part D data, Lucentis costs $654.00 per claim, which is 13% less than Eylea at $752.00 per claim.
Medicare spent $3.7B on Eylea and $1.1B on Lucentis. In terms of patient reach, Eylea serves more beneficiaries (685,000 vs 245,000).
Year-over-year spending changed -8.3% for Eylea and -22.3% for Lucentis.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Lucentis is cheaper at $654.00 per claim, compared to $752.00 for Eylea. That makes Lucentis about 13% less expensive per claim based on Medicare Part D data.
Yes, both Eylea and Lucentis are used to treat eye diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Aflibercept and generic Ranibizumab can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $3.7B on Eylea covering 685,000 beneficiaries, and $1.1B on Lucentis covering 245,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Eylea and Lucentis on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.